NEW YORK, NY, January 13, 2025 /24-7PressRelease/ -- Tom J. Mullen, MBA, founder and CEO of RxMarketSCIENCE, has been selected for inclusion in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Mr. Mullen is a distinguished pharmaceutical business strategy & policy expert, with a particular focus on the economics of pharmaceutical and biotech commerce. His work focuses on the end-to-end economics and lifecycle of drugs, from their manufacturing to the pharmaceutical health outcome of patients, encompassing the whole aspects of the business of medicines. As the founder and CEO of RxMarketSCIENCE, an industry, policy and strategy research and advisory firm, he has dedicated his career to studying and analyzing the business of medicines, which includes the flow of products, money and information within the health care system that ultimately affects pharmaceutical access, cost and patient health outcomes. His expertise is sought after by fortune 500 companies, general management consulting firms and investment firms for gaining insight into drug industry dynamics for policy making as well as for strategic business decision making. Additionally, he collaborates with corporations and private equity firms to assess potential investments and grow their portfolio businesses in the broader pharmaceutical and biotech industry.
Previously, Mr. Mullen served as the director of strategy and business development at the McKesson Corporation where he was recognized as one of the top 35 young executives who are considered as high potential leaders. Prior to McKesson, he has been instrumental in developing and implementing growth and value creation strategies for various small and midsize firms which resulted in acquisition of those firms by Fortune 500 companies and private equity firms. He was invited to speak on the evolution of the drug wholesaling industry and sit as a panel member at the World Generic Medicines Congress in Washington DC in 2012 which was attended by Congressman Waxman, who was instrumental in the passage of 1984 Hatch-Waxman Act that resulted in the modern generic medicines industry as we see it today and made expensive drugs accessible to millions of people. Mr. Mullen's works have been often recognized for his business model innovations and strategic thinking acumen. In 2018, he was hosted by the Bavarian Government in Munich, Germany as a health-biopharma industry expert from the U.S. to be part of the "Invest in Bavaria" delegation to assess the suitability of Bavarian entrepreneurship eco-system for US based Healthcare companies to expand into European markets. Recently, Mr. Mullen has been hosted by Singapore Government's Economic Development Board as part of a delegation that studied the potential of public-private partnership models as a possible solution to address many of the problems we see in the pharmaceutical benefits and healthcare industry in the US. Prior to focusing on pharmaceutical and biotech industries, Mr. Mullen has advised and assisted with strategy development for several global businesses, such as Toyota Financial Services, Panasonic Corporation, GE Energy, Emitech GMbH, GE Capital, Textron, and Kinetic Honda Motors in addition to various firms in the US , Europe, Israel and Asia. Originally trained as a Mechanical and Control Systems Engineer, Mr. Mullen started his career as a researcher and scientist in one of India's premier research institutions under the Ministry of Industries where he was instrumental in leading the institute's first ever international research project and turning the non-profit body into a profitable organization.
Mr. Mullen's academic background is extensive, with various academic credentials contributing to his professional success. He holds a Master of Science in pharmaceutical outcomes and policy from the College of Pharmacy at the University of Florida, a Master of Business Administration in finance and strategy from the Ross School of Business at the University of Michigan, and dual Master of Science in Engineering degrees, from the Rackham Graduate School at the University of Michigan. He attributes his success and passion to learn to his foundational education - Bachelor of Technology in mechanical engineering from Mar Athanasius College of Engineering at Mahatma Gandhi University, one of India's prestigious engineering institutions established under an unique public-private partnership model. In order to support research initiatives at RxMarketSCIENCE, currently, Mr. Mullen is pursuing a Doctorate in Business Administration specializing in strategic management at the Warrington College of Business at the University of Florida, where his academic research focuses on the effects of middlemen, platform business models and market design firms on the pharmaceutical costs, patient access and the economics of the drug industry, with the ultimate goal of helping the pharmaceutical and biotech industry leaders and lawmakers find solutions to some of the most pressing issues in US healthcare.
In addition to his academic achievements, Mr. Mullen has obtained several advanced training, including a specialized training in the business of life sciences from the Center for Business of Life Sciences at Indiana University, and three graduate certificates in applied pharmacoeconomics, managed care pharmacy systems and pharmaceutical regulations from the University of Florida College of Pharmacy. Mr. Mullen is a visionary leader dedicated to transforming the pharmaceutical and healthcare business landscape. Guided by the belief that the drug business is fundamentally different from any other business due to its profound impact on human lives, he emphasizes the ethical balance between corporate profit and patient access. While he acknowledges that businesses cannot survive without financial sustainability, he strongly advocates that restricting access or making medicines unaffordable is not a viable and sustainable solution. Mr. Mullen views the pharmaceutical business as a unique discipline requiring innovative strategies that harmonize business objectives, patient needs, and ethical considerations. His relentless pursuit of deeply understanding the complexities of the drug industry forms the foundation of his approach to strategy and policy, ensuring sustainable outcomes for both companies and the communities they serve. Through RxMarketSCIENCE, Mr. Mullen leads with a commitment to fostering a future where business success and patient well-being coexist.
About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.
# # #